Literature DB >> 30168617

Nonhuman primate model of persistent erectile and urinary dysfunction following radical prostatectomy: Feasibility of minimally invasive therapy.

Joao P Zambon1,2, Manish Patel1, Ashok Hemal1,2, Gopal Badlani1, Karl-Erik Andersson2, Renata S Magalhaes2, Shannon Lankford2, Ashley Dean2, James Koudy Williams2.   

Abstract

OBJECTIVE: Persistent urinary incontinence (UI) and/or erectile dysfunction (ED) occur in 30-50% of post-radical prostatectomy patients regardless of nerve sparing approaches. Identification of potential treatment options for these patients will require testing in an animal model that develops these chronic conditions. The objective was to characterize a nonhuman primate (NHP) model of persistent post-prostatectomy ED and UI and then test the feasibility of periurethral injection of the chemokine CXCL-12.
METHODS: Ten adult male cynomolgus monkeys were used. Two were used for study of normal male nonhuman primate genitourinary anatomy. Five were used for measures of sexual behavior, peak intra-corporal pressure (ICP), abdominal leak point pressures (ALPP) 3 and 6-months post open radical prostatectomy (ORP). Three additional ORP animals received ultrasound-guided peri-urethral injection of chemokine CXCL12 6 weeks after ORP, and UI/ED evaluated for up to 3 months.
RESULTS: The anatomy, innervation, and vascular supply to the prostate and surrounding tissues of these male NHPs are substantially similar to those of human beings. ORP resulted in complete removal of the prostate gland along with both neurovascular bundles and seminal vesicles while permitting stable restoration of vesico-urethral patency. ORP produced sustained (6 months) decreases in ALPP, ICP's, and sexual function. Transurethral injection of chemokine CXCL12 was feasible and had beneficial effects on erectile and urinary function.
CONCLUSIONS: ORP in NHPs produced persistent erectile and urinary tract dysfunction. Periurethral injection of CXCL-12 was feasible and improved both urinary incontinence and erectile dysfunction and suggests that this model can be used to test new approaches for both conditions.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  chemokine; erectile dysfunction; non-nerve sparing radical prostatectomy; nonhuman primate; periurethral injection; urinary incontinence

Mesh:

Substances:

Year:  2018        PMID: 30168617      PMCID: PMC8261895          DOI: 10.1002/nau.23536

Source DB:  PubMed          Journal:  Neurourol Urodyn        ISSN: 0733-2467            Impact factor:   2.696


  29 in total

Review 1.  Systematic review and meta-analysis of studies reporting potency rates after robot-assisted radical prostatectomy.

Authors:  Vincenzo Ficarra; Giacomo Novara; Thomas E Ahlering; Anthony Costello; James A Eastham; Markus Graefen; Giorgio Guazzoni; Mani Menon; Alexandre Mottrie; Vipul R Patel; Henk Van der Poel; Raymond C Rosen; Ashutosh K Tewari; Timothy G Wilson; Filiberto Zattoni; Francesco Montorsi
Journal:  Eur Urol       Date:  2012-06-01       Impact factor: 20.096

2.  Delivery of human mesenchymal adipose-derived stem cells restores multiple urological dysfunctions in a rat model mimicking radical prostatectomy damages through tissue-specific paracrine mechanisms.

Authors:  René Yiou; Meriem Mahrouf-Yorgov; Céline Trébeau; Marc Zanaty; Cécile Lecointe; Richard Souktani; Patricia Zadigue; Florence Figeac; Anne-Marie Rodriguez
Journal:  Stem Cells       Date:  2015-10-23       Impact factor: 6.277

3.  Vattikuti Institute prostatectomy: a technique of robotic radical prostatectomy: experience in more than 1000 cases.

Authors:  Mani Menon; Ashok K Hemal
Journal:  J Endourol       Date:  2004-09       Impact factor: 2.942

Review 4.  Stem cell therapies in post-prostatectomy erectile dysfunction: a critical review.

Authors:  Naşide Mangır; Levent Türkeri
Journal:  Can J Urol       Date:  2017-02       Impact factor: 1.344

Review 5.  Robot-assisted radical prostatectomy: inching toward gold standard.

Authors:  Akshay Sood; Wooju Jeong; James O Peabody; Ashok K Hemal; Mani Menon
Journal:  Urol Clin North Am       Date:  2014-08-22       Impact factor: 2.241

Review 6.  Animal models of erectile dysfunction (ED): potential utility of non-human primates as a model of atherosclerosis-induced vascular ED.

Authors:  J K Williams; K-E Andersson; G Christ
Journal:  Int J Impot Res       Date:  2011-12-29       Impact factor: 2.896

Review 7.  Stromal cell-derived factor-1 (SDF-1): homing factor for engineered regenerative medicine.

Authors:  Ting Ting Lau; Dong-An Wang
Journal:  Expert Opin Biol Ther       Date:  2011-02       Impact factor: 4.388

8.  Monitoring of erectile and urethral sphincter dysfunctions in a rat model mimicking radical prostatectomy damage.

Authors:  Muhieddine Khodari; Rachid Souktani; Olivier Le Coz; Dina Bedretdinova; Florence Figeac; Adrien Acquistapace; Pierre Francois Lesault; Julie Cognet; Anne Marie Rodriguez; René Yiou
Journal:  J Sex Med       Date:  2012-08-21       Impact factor: 3.802

Review 9.  Role of stromal cell-derived factor 1α pathway in bone metastatic prostate cancer.

Authors:  Nisha Gupta; Dan G Duda
Journal:  J Biomed Res       Date:  2015-11-02

10.  Local versus intravenous injections of skeletal muscle precursor cells in nonhuman primates with acute or chronic intrinsic urinary sphincter deficiency.

Authors:  J Koudy Williams; Gopal Badlani; Ashley Dean; Shannon Lankford; Kimberly Poppante; Tracy Criswell; Karl-Erik Andersson
Journal:  Stem Cell Res Ther       Date:  2016-10-07       Impact factor: 6.832

View more
  2 in total

1.  Screening and identification of critical biomarkers in erectile dysfunction: evidence from bioinformatic analysis.

Authors:  Jialiang Hui; Ruiyu Liu; Haibo Zhang; Shuhua He; Anyang Wei
Journal:  PeerJ       Date:  2020-02-28       Impact factor: 2.984

2.  Vasocutaneous fistula formation and repair following inguinal hernia repair in a rhesus monkey (Macaca mulatta).

Authors:  Parviz K Kavoussi; Gregory Wilkerson; Stanton B Gray
Journal:  J Med Primatol       Date:  2022-02-07       Impact factor: 0.821

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.